Purchase this article with an account.
S. Grisanti, S. Biester, S. Peters, O. Tatar, P. Szurman, S. Aisenbrey, Tuebingen Bevacizumab Study Group; Intraocular Bevacizumab (Avastin): for Rubeosis Iridis . Invest. Ophthalmol. Vis. Sci. 2006;47(13):5219.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To determine whether intraocular bevacizumab decreases vascular leakage and rubeosis iridis in patients with neovascular glaucoma.
The study included 18 eyes of 15 patients with secondary neovascular glaucoma due to proliferative diabetic retinopathy (n=9) or ischemic vessel occlusion (n=8). All patients received an intraocular injection of 1.0 mg of bevacizumab. Intraocular injection was performed in topical anaesthesia either in the anterior chamber (n=11) or via pars plana intravitreally (n=7). Rubeosis iridis and vascular leakage was investigated prospectively by iris fluorescein angiography.
Degree of rubeosis iridis decreased significantly (p<0.01) within 1 week after application. The improvement was maintained for at least 4 weeks. An inflammatory response with fibrinous reaction and pseudohypopyon was observed in one case one day after surgery. The reaction persisted only 1 day. An updated follow–up will be presented at the meeting
Intraocular injection of bevacizumab may provide an additional strategy to the treatment of rubeosis iridis. Its long term effect and impact on neovascular glaucoma has to be determined.
This PDF is available to Subscribers Only